93 related articles for article (PubMed ID: 21070099)
21. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
22. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
23. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer: metastatic.
Johnston S; Stebbing J
Clin Evid; 2002 Dec; (8):1785-810. PubMed ID: 12603970
[No Abstract] [Full Text] [Related]
25. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
26. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
27. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
28. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
29. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
30. Human chorionic gonadotropin (hCG) and prevention of breast cancer.
Janssens JP; Russo J; Russo I; Michiels L; Donders G; Verjans M; Riphagen I; Van den Bossche T; Deleu M; Sieprath P
Mol Cell Endocrinol; 2007 Apr; 269(1-2):93-8. PubMed ID: 17386970
[TBL] [Abstract][Full Text] [Related]
31. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
32. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors in metastatic breast cancer.
Buzdar AU; Plourde PV; Hortobagyi GN
Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
[TBL] [Abstract][Full Text] [Related]
35. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
36. Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Baggett CD; Gogate A; Reeder-Hayes KE; Rotter J; Zhou X; Ekwueme DU; Fairley TL; Wheeler SB
Breast Cancer Res Treat; 2020 Jun; 181(3):653-665. PubMed ID: 32346820
[TBL] [Abstract][Full Text] [Related]
37. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.
Vekeman F; Yameogo ND; Lefebvre P; Bailey RA; McKenzie RS; Piech CT
J Med Econ; 2010; 13(4):673-80. PubMed ID: 21050062
[TBL] [Abstract][Full Text] [Related]
38. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Cardoso F; Senkus-Konefka E; Fallowfield L; Costa A; Castiglione M;
Ann Oncol; 2010 May; 21 Suppl 5():v15-9. PubMed ID: 20555067
[No Abstract] [Full Text] [Related]
39. Health care-related time costs in patients with metastatic breast cancer.
Rocque GB; Williams CP; Ingram SA; Azuero A; Mennemeyer ST; Young Pierce J; Nipp RD; Reeder-Hayes KE; Kenzik KM
Cancer Med; 2020 Nov; 9(22):8423-8431. PubMed ID: 32955793
[TBL] [Abstract][Full Text] [Related]
40. Proceedings of the 3rd International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer.
Clin Cancer Res; 2004 Jan; 10(1 Pt 2):327S-409S; quiz i-iv. PubMed ID: 14981797
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
